Trends in Primary Gallbladder Cancer Incidence and Incidence-based Mortality in the United States, 1973 to 2015.
| Title: | Trends in Primary Gallbladder Cancer Incidence and Incidence-based Mortality in the United States, 1973 to 2015. |
|---|---|
| Authors: | Low SK; Department of Internal Medicine, Rochester General Hospital, Rochester.; Online Research Club ( http://www.onlineresearchclub.org/ ).; Giannis D; The Feinstein Institute for Medical Research.; Department of Surgery, North Shore University Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset.; Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.; Thuong ND; Online Research Club ( http://www.onlineresearchclub.org/ ).; School of Medicine, Vietnam National University Ho Chi Minh City, Vietnam.; Nam NH; Online Research Club ( http://www.onlineresearchclub.org/ ).; Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto.; Alshareef A; Online Research Club ( http://www.onlineresearchclub.org/ ).; Faculty of Medicine, University of Zawia, Azzawiyah, Libya.; Koulas I; The Feinstein Institute for Medical Research.; Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.; Geropoulos G; Department of Thoracic Surgery, University College London Hospitals NHS Foundation Trust, London, UK.; Moris D; Duke Surgery, Duke University Medical Center, Durham, NC.; Molmenti EP; The Feinstein Institute for Medical Research.; Department of Surgery, North Shore University Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset.; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.; Huy NT; School of Tropical Medicine and Global Health, Nagasaki University, Japan. |
| Source: | American journal of clinical oncology [Am J Clin Oncol] 2022 Jul 01; Vol. 45 (7), pp. 306-315. Date of Electronic Publication: 2022 May 19. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8207754 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-453X (Electronic) Linking ISSN: 02773732 NLM ISO Abbreviation: Am J Clin Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: Hagerstown, MD : Lippincott Williams & Wilkins; Original Publication: New York, N.Y. : Masson Pub. USA, c1982- |
| MeSH Terms: | Gallbladder Neoplasms*/epidemiology ; Gallbladder Neoplasms*/therapy ; Biliary Tract Neoplasms*; United States/epidemiology ; Chemotherapy, Adjuvant ; Female ; Humans ; Incidence |
| Abstract: | Objectives: Primary gallbladder cancer (GBC) is the most common biliary tract cancer with poor survival despite aggressive treatment. This study aimed to investigate the trends of GBC incidence and incidence-based mortality (IBM) over the last 4 decades.; Materials and Methods: GBC cases diagnosed between 1973 and 2015 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Incidence rates, IBM rates, and annual percent changes (APCs) were calculated and stratified according to population and tumor characteristics.; Results: The cohort consisted of 10,792 predominantly white (81%) and female (71%) GBC patients. The overall GBC incidence decreased by 1.65% (95% confidence interval [CI]: 1.45% to 1.84%) per year since 1973, but has plateaued since 2002. IBM decreased by 1.69% (95% CI: 1.22% to 2.16%) per year from 1980 to 2015; the rate of decrease in IBM rates was lower during 1997 to 2015 (APC: -1.19%, 95% CI: -1.68% to -0.71%) compared with 1980 to 1997 (APC: -3.13%, 95% CI: -3.68% to -2.58%).; Conclusions: The incidence and IBM rates of GBC have been decreasing over the last 40 years, but the decrease plateaued over the last 2 decades. The effects of treatment modalities, including laparoscopic cholecystectomy, adjuvant chemotherapy, and radiation on the incidence and IBM of GBC need to be further investigated.; (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.) |
| Competing Interests: | The authors declare no conflicts of interest. |
| References: | Baillie J. Tumors of the gallbladder and bile ducts. J Clin Gastroenterol. 1999;29:14–21.; Buettner S, Margonis GA, Kim Y, et al. Changing odds of survival over time among patients undergoing surgical resection of gallbladder carcinoma. Ann Surg Oncol. 2016;23:4401–4409.; Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for gallbladder cancer across the world. HPB. 2008;10:327–331.; Strom BL, Soloway RD, Rios-Dalenz JL, et al. Risk factors for gallbladder cancer. an international collaborative case-control study. Cancer. 1995;76:1747–1756.; Sharma A, Sharma KL, Gupta A, et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol. 2017;23:3978–3998.; Bertran E, Heise K, Andia ME, et al. Gallbladder cancer: incidence and survival in a high-risk area of Chile. Int J Cancer . 2010:127:2446–2454.; Salazar M, Ituarte C, Abriata MG, et al. Gallbladder cancer in South America: epidemiology and prevention. Chin Clin Oncol. 2019;8:32.; Dutta U, Bush N, Kalsi D, et al. Epidemiology of gallbladder cancer in India. Chin Clin Oncol. 2019;8:33.; Tsilimigras DI, Hyer JM, Paredes AZ, et al. The optimal number of lymph nodes to evaluate among patients undergoing surgery for gallbladder cancer: correlating the number of nodes removed with survival in 6531 patients. J Surg Oncol. 2019;119:1099–1107.; Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99–109.; Nemunaitis JM, Brown-Glabeman U, Soares H, et al. Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. BMC Cancer. 2018;18:665.; Cubertafond P, Gainant A, Cucchiaro G. Surgical treatment of 724 carcinomas of the gallbladder. Results of the French Surgical Association Survey. Ann Surg. 1994;219:275–280.; Wang SJ, Fuller CD, Kim JS, et al. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:2112–2117.; Dwivedi AND, Jain S, Dixit R. Gall bladder carcinoma: Aggressive malignancy with protean loco-regional and distant spread. World J Clin Cases WJCC. 2015;3:231–244.; Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data, Nov 2018 Sub (1975-2016) - Linked To County Attributes-Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program. Available at: http://www.seer.cancer.gov . Accessed March 1, 2020.; Rahman R, Simoes EJ, Schmaltz C, et al. Trend analysis and survival of primary gallbladder cancer in the United States: a 1973–2009 population-based study. Cancer Med. 2017;6:874–880.; Jaruvongvanich V, Yang JD, Peeraphatdit T, et al. The incidence rates and survival of gallbladder cancer in the USA. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2019;28:1–9.; Gordon-Dseagu VL, Devesa SS, Goggins M, et al. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018;47:427–439.; Chu KC, Miller BA, Feuer EJ, et al. A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol. 1994;47:1451–1461.; Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg Lond Engl. 2014;12:1500–1524.; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute; 2019. Joinpoint Regression Program. Available at: https://surveillance.cancer.gov/joinpoint/ . Accessed June 2019.; Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335–351.; Shaffer E, Hundal R. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol . 2014;6:99–109.; Shaffer EA. Gallbladder cancer: the basics. Gastroenterol Hepatol. 2008;4:737–741.; Lazcano-Ponce EC, Miquel JF, Muñoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349–364.; Cavallaro A, Piccolo G, Di Vita M, et al. Managing the incidentally detected gallbladder cancer: Algorithms and controversies. Int J Surg. 2014;12:S108–S119.; Lau CSM, Zywot A, Mahendraraj K, et al. Gallbladder carcinoma in the United States: a population based clinical outcomes study involving 22,343 patients from the Surveillance, Epidemiology, and End Result Database (1973–2013). HPB Surg. 2017;2017:1–7.; Yagyu K, Kikuchi S, Obata Y, et al. Cigarette smoking, alcohol drinking and the risk of gallbladder cancer death: a prospective cohort study in Japan. Int J Cancer. 2008;122:924–929.; Lugo A, Peveri G, Gallus S. Should we consider gallbladder cancer a new smoking-related cancer? A comprehensive meta-analysis focused on dose–response relationships. Int J Cancer. 2019;146:3304–3311.; Jain K, Sreenivas V, Velpandian T, et al. Risk factors for gallbladder cancer: a case–control study. Int J Cancer. 2013;132:1660–1666.; Ranelletti FO, Piantelli M, Farinon AM, et al. Estrogen and progesterone receptors in the gallbladders from patients with gallstones. Hepatol Baltim Md. 1991;14(pt 1):608–612.; Moore SP, Forman D, Piñeros M, et al. Cancer in indigenous people in Latin America and the Caribbean: a review. Cancer Med. 2014;3:70–80.; Ikoma T, Tsuchiya Y, Asai T, et al. Ochratoxin A contamination of red chili peppers from Chile, Bolivia and Peru, countries with a high incidence of gallbladder cancer. Asian Pac J Cancer Prev. 2015;16:5987–5991.; Henley SJ, Weir HK, Jim MA, et al. Gallbladder cancer incidence and mortality, United States 1999-2011. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2015;24:1319–1326.; Castro FA, Koshiol J, Hsing AW, et al. Biliary tract cancer incidence in the United States Demographic and temporal variations by anatomic site. Int J Cancer. 2013;133:1664–1671.; Le MD, Henson D, Young H, et al. Is gallbladder cancer decreasing in view of increasing laparoscopic cholecystectomy? Ann Hepatol. 2011;10:306–314.; Jaruvongvanich V, Assavapongpaiboon B, Wong L. Racial/ethnic disparities in gallbladder cancer receipt of treatments. J Gastrointest Oncol. 2018;9:348–353.; Duffy A, Capanu M, Abou-Alfa GK, et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. 2008;98:485–489.; Rizwan Khan M, Ahsan Raza S, Ahmad Z, et al. Gallbladder intestinal metaplasia in Pakistani patients with gallstones. Int J Surg. 2011;9:482–485.; Alvi AR, Siddiqui NA, Zafar H. Risk factors of gallbladder cancer in Karachi-a case-control study. World J Surg Oncol. 2011;9:164.; Fuks D, Regimbeau JM, Le Treut YP, et al. Incidental gallbladder cancer by the AFC-GBC-2009 Study Group. World J Surg. 2011;35:1887–1897.; de Aretxabala XA, Roa IS, Mora JP, et al. Laparoscopic cholecystectomy: its effect on the prognosis of patients with gallbladder cancer. World J Surg. 2004;28:544–547.; Reynolds W. The first laparoscopic cholecystectomy. JSLS. 2001;5:89–94.; Polychronidis A, Laftsidis P, Bounovas A, et al. Twenty years of laparoscopic cholecystectomy: Philippe Mouret—March 17, 1987. JSLS. 2008;12:109–111.; Moris D, Pappas TN. Time to revisit indications for cholecystectomy. Lancet. 2019;394:1803–1804.; Huang J, Patel HK, Boakye D, et al. Worldwide distribution, associated factors, and trends of gallbladder cancer: a global country-level analysis. Cancer Lett. 2021;521:238–251.; Randi G, Malvezzi M, Levi F, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol Off J Eur Soc Med Oncol. 2009;20:146–159.; Alexander S, Lemmens VEPP, Houterman S, et al. Gallbladder cancer, a vanishing disease? Cancer Causes Control CCC. 2012;23:1705–1709.; Legorreta AP, Silber JH, Costantino GN, et al. Increased cholecystectomy rate after the introduction of laparoscopic cholecystectomy. JAMA. 1993;270:1429–1432.; Torre LA, Siegel RL, Islami F, et al. Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2018;16:427–437.; Bodmer M, Brauchli YB, Krähenbühl S, et al. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA. 2009;302:2001–2007.; Benson AB, D’Angelica MI, Abbott DE, et al. Guidelines insights: hepatobiliary cancers, Version 2.2019. J Natl Compr Cancer Netw JNCCN. 2019;17:302–310.; Giannis D, Cerullo M, Moris D, et al. Validation of the 8th Edition American Joint Commission on Cancer (AJCC) gallbladder cancer staging system: prognostic discrimination and identification of key predictive factors. Cancers (Basel). 2021;13:547.; Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–673.; Wang L, Dong P, Zhang Y, et al. Prognostic validation of the updated 8th edition Tumor-Node-Metastasis classification by the Union for International Cancer Control: Survival analyses of 307 patients with surgically treated gallbladder carcinoma. Oncol Lett. 2018;16:4427–4433.; D’Angelica M, Dalal KM, DeMatteo RP, et al. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2009;16:806–816.; Benson AB, D’Angelica MI, Abbott DE, et al. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Cancer Netw JNCCN. 2017;15:563–573.; Ethun CG, Postlewait LM, Le N, et al. Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium. JAMA Surg. 2017;152:143–149.; Sahara K, Tsilimigras DI, Maithel SK, et al. Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: an analysis of the US extrahepatic biliary malignancy consortium. J Surg Oncol. 2020;121:503–510.; You DD, Lee HG, Paik KY, et al. What is an adequate extent of resection for T1 gallbladder cancers? Ann Surg. 2008;247:835–838.; Liu GJ, Li XH, Chen YX, et al. Radical lymph node dissection and assessment: impact on gallbladder cancer prognosis. World J Gastroenterol WJG. 2013;19:5150–5158.; Negi SS, Singh A, Chaudhary A. Lymph nodal involvement as prognostic factor in gallbladder cancer: location, count or ratio? J Gastrointest Surg Off J Soc Surg Aliment Tract. 2011;15:1017–1025.; Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–99.; Berger-Richardson D, Chesney TR, Englesakis M, et al. Trends in port-site metastasis after laparoscopic resection of incidental gallbladder cancer: a systematic review. Surgery. 2017;161:618–627.; Ethun CG, Postlewait LM, Le N, et al. Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium. J Surg Oncol. 2017;115:805–811.; Maker AV, Butte JM, Oxenberg J, et al. Is port site resection necessary in the surgical management of gallbladder cancer? Ann Surg Oncol. 2012;19:409–417.; Hakeem AR, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer—a systematic review. Eur J Surg Oncol. 2019;45:83–91.; Kim TH, Woo SM, Lee WJ, et al. Benefit of adjuvant chemoradiotherapy in resected gallbladder carcinoma. Sci Rep. 2019;9:11770.; Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:1934–1940.; Geng ZM, Cai ZQ, Zhang Z, et al. Estimating survival benefit of adjuvant therapy based on a Bayesian network prediction model in curatively resected advanced gallbladder adenocarcinoma. World J Gastroenterol. 2019;25:5655–5666.; Tran Cao HS, Zhang Q, Sada YH, et al. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. Cancer. 2018;124:74–83.; Wang SJ, Lemieux A, Kalpathy-Cramer J, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:4627–4632.; Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281.; Canale M, Monti M, Rapposelli IG, et al. Molecular targets and emerging therapies for advanced gallbladder cancer. Cancers (Basel). 2021;13:5671.; Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol Off J Eur Soc Med Oncol. 2019;30:1950–1958.; Sakai D, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol. 2018;29(suppl 8):viii205–viii270.; Margonis GA, Gani F, Buettner S, et al. Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. HPB. 2016;18:872–878.; Chijiiwa K, Sumiyoshi K, Nakayama F. Impact of recent advances in hepatobiliary imaging techniques on the preoperative diagnosis of carcinoma of the gallbladder. World J Surg. 1991;15:322–327.; Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 2007;11:671–681.; Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118:1591–1602.; Levi F, Lucchini F, Negri E, et al. The recent decline in gallbladder cancer mortality in Europe. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2003;12:265–267.; Lee SE, Jang JY, Lim CS, et al. Systematic review on the surgical treatment for T1 gallbladder cancer. World J Gastroenterol. 2011;17:174–180.; Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70:1493–1497.; Rawla P, Sunkara T, Thandra KC, et al. Epidemiology of gallbladder cancer. Clin Exp Hepatol. 2019;5:93–102.; Murakami Y, Uemura K, Sudo T, et al. Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection. J Gastrointest Surg. 2011;15:1007–1016.; Chan SY, Poon RTP, Lo CM, et al. Management of carcinoma of the gallbladder: a single-institution experience in 16 years. J Surg Oncol. 2008;97:156–164.; Ito H, Matros E, Brooks DC, et al. Treatment outcomes associated with surgery for gallbladder cancer: a 20-year experience. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2004;8:183–190.; Azizi AA, Lamarca A, Valle JW. Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer. Chin Clin Oncol. 2019;8:43.; Kim BH, Kwon J, Chie EK, et al. Adjuvant chemoradiotherapy is associated with improved survival for patients with resected gallbladder carcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018;25:255–264.; Messina C, Merz V, Frisinghelli M, et al. Adjuvant chemotherapy in resected bile duct cancer: a systematic review and meta-analysis of randomized trials. Crit Rev Oncol Hematol. 2019;143:124–129.; Incidence-Based Mortality. Available at: https://surveillance.cancer.gov/statistics/ibm/ . Accessed March 1, 2022. |
| Entry Date(s): | Date Created: 20220614 Date Completed: 20220623 Latest Revision: 20220804 |
| Update Code: | 20260130 |
| DOI: | 10.1097/COC.0000000000000918 |
| PMID: | 35700074 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't